RIPK3 and metabolic dysfunction-associated steatohepatitis: However, our present findings on the unexpected role of RIPK3 in WAT suggest that systemic pharmacological targeting of RIPK3 in NASH patients—as well as in other necroptosis-related diseases10—might cause or aggravate glucose intolerance and insulin resistance in obese individuals.